

RESEARCH ARTICLE

Open Access

Mapping the deletion endpoints in individuals with 22q11.2 Deletion Syndrome by droplet digital PCR

Vicki J Hwang^{1†}, Dianna Maar^{2†}, John Regan², Kathleen Angkustsiri⁴, Tony J Simon^{3,5} and Flora Tassone^{1,3*}

Abstract

Background: Chromosome 22q11.2 deletion syndrome (22q11DS) is the most common human microdeletion syndrome and is associated with many cognitive, neurological and psychiatric disorders. The majority of individuals have a 3 Mb deletion while others have a nested 1.5 Mb deletion, but rare atypical deletions have also been described. To date, a study using droplet digital PCR (ddPCR) has not been conducted to systematically map the chromosomal breakpoints in individuals with 22q11DS, which would provide important genotypic insight into the various phenotypes observed in this syndrome.

Methods: This study uses ddPCR to assess copy number (CN) changes within the chromosome 22q11 deletion region and allows the mapping of the deletion endpoints. We used eight TaqMan assays interspersed throughout the deleted region of 22q11.2 to characterize the deleted region of chromosome 22 in 80 individuals known to have 22q11DS by FISH. Ten EvaGreen assays were used for finer mapping of the six identified individuals with 22q11DS atypical deletions and covering different regions of chromosome 22.

Results: ddPCR provided non-ambiguous CN measurements across the region, confirmed the presence of the deletion in the individuals screened, and led to the identification of five differently sized and located deletions. The majority of the participants (n = 74) had the large 3 Mb deletions, whereas three had the smaller 1.5 Mb deletions, and the remaining three had an interstitial deletion of different size.

Conclusions: The lower cost, rapid execution and high reliability and specificity provided by ddPCR for CN measurements in the 22q11 region constitutes a significant improvement over the variable CN values generated by other technologies. The ability of the ddPCR approach, to provide a high resolution mapping of deletion endpoints may result in the identification of genes that are haplo-insufficient and play a role in the pathogenesis of 22q11DS. Finally, this methodology can be applied to the characterization of other microdeletions throughout the genome.

Keywords: Droplet digital PCR, 22q11DS, qPCR, copy number, LCR

Background

Chromosome 22q11.2 Deletion Syndrome (22q11DS) is the most frequent microdeletion syndrome in humans with an estimated prevalence of 1:3000–1:6000 live births [1–4]. A wide array of phenotypes has been associated with this syndrome including structural malformations (congenital

heart disease (CHD), thyroid abnormalities, and hypocalcemia) and neurodevelopmental and neurological deficits (Intellectual Disabilities (ID), Attention Deficit Hyperactivity Disorder (ADHD) and seizures) [5].

The majority of 22q11 deletions arise *de novo* (90%) and only a small minority (10%) is inherited. The high frequency of *de novo* events has been attributed to the high mutation-rearrangement rate associated with several low copy repeat (LCR) regions throughout the 22q deletion region [6,7]. The LCRs found in 22q are larger and have higher sequence similarity than most other LCR regions in the genome, possibly explaining the

* Correspondence: ftassone@ucdavis.edu

†Equal contributors

¹Department of Biochemistry and Molecular Medicine, UC Davis, 2700 Stockton Blvd, Suite 2102, Sacramento, CA 95817, USA

³MIND Institute, UC Davis Medical Center, Wet Lab Room 2418, 2805 50th Street, Sacramento, CA 95817, USA

Full list of author information is available at the end of the article

higher prevalence of 22q11DS in the general population compared to other chromosomal deletion syndromes [8,9]. It is thought that the majority of individuals with 22q11DS have deletion breakpoints located within the 22q11 LCRs. Indeed, 70-80% of these individuals have the 3 Mb deletion (between LCR A and D), 10-15% have a nested 1.5 Mb deletion (between LCR A and B), and the remaining have atypical deletions [7,10-33]. These deletions are likely the results of unequal crossing-over during meiosis involving smaller LCRs within the deleted regions.

Multiple studies have attempted to delineate the deletion endpoints in individuals with 22q11DS; however, the difficulty in designing unique primers or identifying unique SNPs in the proximity or within these repeat regions has hindered the progress of locating the exact position of the deletion endpoints which remains poorly defined [10,34-36].

Several studies have also attempted to elucidate genotype-phenotype correlations among individuals with 22q11DS or to identify a minimal region of disease, but these correlations are still not well understood [12,15]. Reports of individuals with different size deletions that cover nearby, non-overlapping regions and presenting with similar clinical phenotypes stress the importance of delineating the exact deletion endpoints in order to accurately bin individuals and specific phenotypes. Specifically, Amati et al. [14] and Yamagishi et al. [20] described several cases with different, adjacent deletions located between LCR-A and LCR-B that presented with CHD and facial dysmorphism. These observations suggest that a minimal critical region for these phenotypes that exists between LCR-A and LCR-B. The need for better genotype and phenotype correlations in individuals with 22q11DS makes it important to screen a large cohort with high resolution in order to determine the exact deletion breakpoints and to correctly identify those regions that may correlate to specific phenotypes.

So far, the methodologies utilized for gene copy number quantification have often given inconsistent results in target populations. Currently, the gold standard method of diagnosis for 22q11DS is by fluorescent *in-situ* hybridization (FISH) [5,37]. However, this approach is labor intensive, expensive, requires specialized and well trained technicians and equipment, and may not identify a small portion of individuals with 22q11DS. In addition, it is difficult to adopt FISH in a high throughput setting. Other methodologies currently used to determine the presence of a deletion and to delineate the endpoints for 22q11DS include: multiplex ligation-dependent probe amplification (MLPA) [38], quantitative PCR (qPCR) [35], and multiple types of chromosomal arrays (single nucleotide polymorphisms microarrays, (SNPs) and array-based comparative genomic hybridization, aCGH) [39]. However,

none of these have been shown to be high-throughput, robust and cost-effective. Specifically, the high cost and technical complexity of the CGH array make it unsuitable for routine diagnostic use and for high throughput testing. Various steps have been found to be critical and limiting for the performance of MLPA including the choice of the reference DNA, incomplete denaturation, and sensitivity to DNA and salt concentration [40,41]. Lastly, qPCR is prone to false positive results, perhaps due to the limited efficiency of the oligonucleotide probes, nucleotide content of the target region and susceptibility to inhibitors [42,43].

Droplet digital PCR (ddPCR) is a new approach to nucleic acid detection and quantification and gives extremely robust values as samples are partitioned into approximately 20,000 water-in-oil droplets, allowing many thousands of discrete measurements to be made. Additionally, as the partitioning of a DNA sample allows for an independent reaction in each droplet, robust CN measurements with 95% confidence can be generated. The binary nature of ddPCR makes it tolerant to differences in PCR amplification efficiency, often allowing for no overlap of 95% confidence intervals for adjacent copy number states [44] and has been demonstrated to possess a high level of accuracy and precision for determining copy number quantification [45]. Finally, as multiplexing can be easily performed using ddPCR, the ~4\$ cost per sample allows not only the detection of 22q11DS but simultaneously allows the differentiation between the two common deletions (3 Mb and 1.5 Mb).

In this study, we utilized ddPCR for CN value measurements at different locations within the 22q11.2 region to finely map the deletion breakpoints in 80 individuals with 22q11DS. We demonstrate that ddPCR is a precise and reliable approach for detecting CN variation within the 22q11 locus (using either Taqman or EvaGreen assays) and that ddPCR can be used to delineate the deletion endpoints, which may be helpful in identifying the critical regions corresponding to disease. We also used ddPCR to study genotype-phenotype correlations in 22q11DS and to examine its application for diagnostic and clinical purposes.

Methods

Human participants

Participants were recruited at the UC Davis Medical Investigation of Neurodevelopmental Disorders (MIND) Institute located in Sacramento, under written consent from the next of kin, caretakers, or guardians on the behalf of the minors/children participants and according to a UC Davis Institutional Review Board (IRB) approved protocol. The diagnosis of 22q11DS was obtained for the participants by FISH analysis using the *TUPLE1* probe. No information on the size and the position of the

deleted region was available. A retrospective blinded study using ddPCR was conducted in order to determine the deletion status of participants with 22q11DS. 95 participants, including 80 individuals (48 males and 32 females) with 22q11DS and 15 TD controls (8 males and 7 females) were chosen. Age range was 7–15 for 22q11DS and 8–14 for TD. Demographic and clinical diagnoses are shown in Table 1.

Clinical measures

All participants with 22q11DS were examined by a developmental behavioral pediatrician (DBP) or child and adolescent psychiatrist and also underwent neuropsychological assessment, including FSIQ using the WISC-4 [46]. FSIQ ≤ 70 (2 standard deviations below normed means) was used to define abnormally low FSIQ in line with accepted classifications for mental retardation/intellectual disability. Presence of physical conditions (neurologic, cardiac, endocrine, etc.) was obtained from medical history from the parents during the visit with the DBP or psychiatrist, including current and past medications, and when available, medical record abstraction. Examples of abnormal medical conditions included seizures and congenital heart disease such as Tetralogy of Fallot, Truncus Arteriosus, and septal defects. Endocrine disturbances such as hypocalcemia and hyper/hypothyroidism were also documented. Participants were considered to have ADHD if scores on the parent-completed SNAP-IV [47] were above the 95% cutoff for ADHD-inattentive, ADHD-hyperactive, or ADHD-combined type. All TD participants had FSIQ > 85 on the WASI [48].

DNA isolation

Genomic DNA (gDNA) from 80 individuals with 22q11DS and 15 TD individuals was isolated from 3–5 mL of peripheral blood leukocytes using standard procedure (Qiagen, Valencia, CA).

ddPCR

ddPCR involves partitioning the PCR reaction mix into uniform-size droplets, thermal cycling to end-point fluorescence and then singulating and reading the fluorescence of each droplet. Using an assay specific to amplify the DNA targets of interest will result in a fluorescent signal derived from the droplets that contain the DNA target while no signal will be detected from those that do not contain target DNA. Thus, each droplet is counted and able to report an actual number of copies in the sample. For the TaqMan reactions, 2 μ g of gDNA was digested at 37°C for 1 hour, with MseI in NEB Buffer 2.1, in a final volume of 10 μ L. An assay mix containing 100 ng of digested gDNA, Droplet PCR supermix (BioRad Laboratories, Hercules, CA), and gene assay at a final concentration of 900 nM per primer

and 250 nM probe in a 25 μ L final volume was prepared. For the EvaGreen reactions, an assay mix containing 100 ng of gDNA, 5 units MseI, QX200 ddPCR EvaGreen supermix (BioRad Laboratories, Hercules, CA), and gene assay at a final concentration of 100 nM per primer in a 25 μ L final volume was prepared. 20 μ L of assay mix and 70 μ L of ddPCR droplet oil (BioRad Laboratories, Hercules, CA) were transferred onto a QX100/200 DG cartridge (BioRad Laboratories, Hercules, CA), then loaded into the QX100 Droplet Generator (BioRad Laboratories, Hercules, CA). Vacuum was applied, pulling individual samples and oil through a flow-focusing junction to produce $\sim 20,000$ water-in-oil droplets. 40 μ L of the oil and sample droplet emulsions were then transferred into a 96 well plate and thermocycled in a standard thermocycler (BioRad Laboratories, Hercules, CA) for 95°C for 10 minutes, 94°C for 1 min and 59°C for 1 min (repeated 40 times) and 98°C for 10 minutes (TaqMan reactions) or 95°C for 5 minutes, 96°C for 30 seconds and 60°C for 1 minute (repeated 40 times), 4°C for 5 minutes and 90°C for 5 minutes (EvaGreen reactions). The plate was then transferred to a QX200 Droplet Reader (BioRad Laboratories, Hercules, CA) and analyzed by QuantaSoft (BioRad Laboratories, Hercules, CA). For the TaqMan assays, the presence of 2 copies of any given gene region was scored by a CNV value of 2 ± 0.1 and a hemizygous deletion (1 copy) of a region was scored by a CNV value of 1 ± 0.1 . For the EvaGreen assays, a hemizygous deletion of a region was scored by a CNV value of 1 ± 0.4 . TaqMan target primers were designed as described by Weksberg et al. [35]. *D22S181*, *PRODH*, and *D22S936* were specifically chosen to help elucidate the position of the deletion breakpoints. *RPP30*, a reference assay commonly used in ddPCR CNV studies, as it is located in a conserved region on the genome not known to undergo copy number variation, was used as the control [44]. The control probe (*RPP30*) was labeled with VIC and all target probes were labeled with FAM unless otherwise described. TaqMan and EvaGreen primer sequences were as shown in Tables 2 and 3.

To calculate CN measurements for the TaqMan assays, automatic thresholding in Quantasoft was performed on the 2D fluorescent amplitude plot (Figure 1). CN was calculated as $(a/b)^c$ where “a” is the copy of DNA target gene (assays 1–8) per microliter, “b” is the copy of the reference gene (*RPP30*) per microliter and “c” is the CN of the reference gene per genome. Average CN values for all assays are reported in Table 4. To calculate CN measurements for the EvaGreen assays, CN was calculated as $(d/e)^2$ where “d” is the concentration of the target assay and “e” is the concentration of the reference assay (Table 5).

Quantitative PCR

Genomic DNA (gDNA) in a subgroup of 40 participants with 22q11DS was analyzed by qPCR using the methods

Table 1 Demographic information and clinical diagnoses

Dx	No subjects	Gender	Age range	Deletion		Severity	Phenotypes					
				Range	Type		IQn = 78	ADHD n = 79	Seizures n = 79	CHD n = 80	Hypocalcemia n = 78	Thyroid abnormalities n = 79
22q	80	M = 48 F = 32	M = 7-15 F = 8-15	PRODH-D22S936	3 Mb deletion	Normal	45 (58%)	47 (59%)	59 (75%)	38 (47%)	50 (64%)	62 (78%)
						Abnormal	27 (35%)	26 (33%)	14 (18%)	36 (45%)	22 (28%)	11 (14%)
				PRODH-DGCR6L	1.5 Mb deletion	Normal	1 (1.3%)	0	2 (2.5%)	2 (2.5%)	3 (4%)	3 (4%)
						Abnormal	2 (3%)	3 (4%)	1 (1.3%)	1 (1.3%)	0	0
				TUPLE1-SHGC-2421	Atypical deletion	Normal	1 (1.3%)	0	0	0	0	1 (1.3%)
						Abnormal	0	1 (1.3%)	1 (1.3%)	1 (1.3%)	1 (1.3%)	0
				TUPLE1-D22S936	Atypical deletion	Normal	1 (1.3%)	1 (1.3%)	1 (1.3%)	1 (1.3%)	1 (1.3%)	1 (1.3%)
						Abnormal	0	0	0	0	0	0
				ZNF74-D22S936	Atypical deletion	Normal	0	1 (1.3%)	1 (1.3%)	1 (1.3%)	1 (1.3%)	1 (1.3%)
						Abnormal	1 (1.3%)	0	0	0	0	0
TD	15	M = 8 F = 7	M = 8-14 F = 9-13	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Demographic information, size of the deletion, Number and percent of individuals presenting with specific clinical involvement including IQ, ADHD, seizures, CHD, hypocalcemia and thyroid abnormalities are shown.

Table 2 TaqMan primer sequences

Gene	Forward primer	Reverse primer
D22S182	5'- CAGCTCCCAAG TCTTCCAGC -3'	5'- CCAGGGTAGGA AACAGGTCGA -3'
PRODH	5'- GGGAAAGGAG AGTTCAGGCAG -3'	5'- GCTTGTTGAATAG CCTCTGTCTAG -3'
TUPLE1	5'- GGCAAGTGCAAT ATTCATGTGGT -3'	5'- TCCTACACGCC TGACAAAGCT -3'
COMT	5'- GTGCTACTGGCT GACAACGTGAT -3'	5'- GGAACGATTGGT AGTGTGTGCA -3'
ZNF74	5'- TGGCCTCCTGCT TCTTCTTC -3'	5'- CAGACACTCCAAT TCATGACGAA -3'
PIK4C4	5'- ATGCTTGTGCG ACGCAGAC -3'	5'- CCTCAGCCATGTTG ACTCAGC -3'
D22S936	5'- TGGCAGCCAGT TTAGTATTCTGC -3'	5'- TTGTAATCAAGTCC CGCCACT -3'
VPREB1	5'- CGACCATGACA TCGGTGTGT -3'	5'- CTGGCTCTGTCTG ATTGTGAGA -3'

described in Weksberg et al. [35] with minor modifications. Target assays used from Weksberg et al. [35] were the same as those used for ddPCR and reference assays used were *HEM3* and *G6PDH* (2005). For each sample, quantitative-PCR reactions were performed in two independent runs in duplicates. Control reactions were run in parallel. Reactions were performed using FastStart Universal SYBR Green Master Mix (Roche, Applied Science, Indianapolis, IN) (which includes the internal reference (ROX), forward and reverse primers at final concentrations of 800 nM for the target primers and 400 nM for the reference primers, and 10 ng of genomic DNA. The qPCR reactions were run using the Applied Biosystems 7900HT FAST real-time PCR system (Foster City, CA) with 2 min at 50°C, 10 min at 95°C followed by 40 cycles of 15 sec at 95°C and 60 sec at 60°C.

Statistical analysis

QuantaSoft software (version 1.3.2) (Bio-Rad Laboratories, Hercules, CA) was used to analyze the ddPCR data and to calculate the copy number estimations. qPCR data was analyzed using the comparative Ct method after data normalization [35].

Results and discussion

Deletion endpoints


To characterize the size and the location of deletions of 80 individuals known to have 22q11DS by FISH, we used ddPCR to define their deletion endpoints. In this study, 15 typically developing (TD) individuals were used as controls in this study. Our analysis involved 8 loci spanning an approximately 4 Mb region of chromosome 22q11.2. The two outermost genes are thought to be unaltered in individuals with 22q11DS (*D22S181* and *VPREB1*). In all cases, 2 copies of chromosome 22 were

Table 3 EvaGreen primer sequences

Gene	Forward primer	Reverse primer
DGCR8	5'- ATGTGTTCTTC TGCTCTGAT- 3'	5'- CTTACTACAGAG GAAGCATGAAG - 3'
TRMT2A	5'- TTTTGCTCACCT TCCTGTT- 3'	5'- CTGGCAGTCAAA CAAGAGGA- 3'
RANBP1	5'- GAGTGCAGCAG TGGTATCAT- 3'	5'- GATGGCTAACAC CCGTAGTC- 3'
ZDHC8	5'- CTTTCATGGACC CTGGTGT- 3'	5'- TCCCTAAGGCTG TCTCAAGT- 3'
LOC284865	5'- GCCTTGACCTCT GTTTCTGT- 3'	5'- CCCAAGAAGAA AGAGGCACA- 3'
RTN4R	5'- TGATGTGAGAA GGTCCTCCA- 3'	5'- CTGCTTCCCTCA GTTGAAAA- 3'
DGCR6L	5'- AGTGTTCCGAA GAGGTCTCT- 3'	5'- AACAAAAGTGG TTGGACCCA- 3'
SCARF2	5'- TAGGGCCAGTC TATCCCATC- 3'	5'- TTCACAAGCAG GCTTGGATT- 3'
SHGC-2421	5'- TCATGTGGGTG CTGGTAC- 3'	5'- TCCTTGACCA GGCAAC - 3'
HIC2	5'- GAGTCCCTCAG AGAATGGC- 3'	5'- GCCCTGTGGA AGCCTG- 3'

detected in the TD (Figure 2A) and either the 3 Mb (Figure 2B) or 1.5 Mb (Figure 2C) deletions were identified in the individuals with 22q11DS with no ambiguity. We found that 74 individuals carried the 3 Mb deletion and had 1 copy of the 6 genes located within the deleted region and 2 copies of the 2 genes located outside (*D22S181* and *VPREB1*; Figure 2B,C and Figure 3). The remaining 6 individuals with 22q11DS, 3 with the 1.5 Mb deletion and 3 with an interstitial (non-contiguous interspersed deletions) deletion presented with 1 copy of those genes located within the specific deleted region (Figure 2C, and Figure 3). Finally, 15 typically developing (TD) control individuals showed the presence of 2 copies of the 8 genes tested except for one individual who showed a duplication of the *PRODH* gene. The types of deletion found in the individuals in our study samples represent the expected distribution in the 22q11DS population, as we found 92% of individuals having the 3 Mb deletion, 4% having the 1.5 Mb deletion, and 4% having atypical deletions. The majority of individuals had deletions encompassing *PRODH* and *D22S936* with deletion breakpoints near or within LCR-A and LCR-D. None of the 80 samples had a distal deletion extending beyond the LCR-A and LCR-D region, supporting the hypothesis that the majority of 22q11DS individuals have deletion breakpoints located near or within those regions.

Interestingly, three individuals carried interstitial deletions of different sizes and locations, likely originating from more rare events involving smaller LCRs present throughout the 22q deleted region. To perform higher



resolution mapping and to narrow down the exact deletion breakpoints, we used ten additional EvaGreen assays to clarify the deletion region for the six individuals with the less common deletions (Figure 3). Specifically, the three individuals with the 1.5 Mb deletion showed a deletion between *PRODH* and *DGCR6L*, and the three individuals with the atypical deletions showed a deletion between *TUPLE1* and *SHGC-2421*, *ZNF74* and *D22S936*, or *TUPLE1* and *D22S936* (Figure 3). Average copy number values are reported in Tables 4 and 5.

Comparison between qPCR and ddPCR

To determine whether ddPCR offers advantages, particularly in performance, reliability and specificity, over qPCR for 22q11DS detection, we analyzed a subgroup of 40 individuals with 22q11DS by qPCR (SYBR Green) using the same eight assays used for ddPCR (Taqman) analysis. qPCR data showed that 18 (53%) of these individuals had non-contiguous interstitial deletions, which were determined to be contiguous by ddPCR. Of the individuals tested, 2 (6%) were determined to have a larger deletion than that resolved by ddPCR and 4 (12%) were determined to have smaller deletions than that resolved by ddPCR. Only 6 (15%) of the qPCR deletion endpoint determinations were the same as those obtained with ddPCR (Figure 4). In respect to the copy number in the *TUPLE1* gene (for comparison with FISH data), ddPCR results for 80 individuals with 22q11DS and 15 TD individuals was found to be 100% specific (Table 6), whereas qPCR results for 19 individuals with 22q11DS and 11 TD individuals was only 58.6% specific (Table 7). Thus,

in our hands, qPCR failed to accurately define the deletion breakpoints, possibly due to its reliance on standard curves and its sensitivity to amplification efficiencies and thus, it may not provide sufficient accuracy to serve as a comprehensive diagnostic tool.

Advantages of TaqMan-based ddPCR include no need for a standard curve, multiple targets and reference gene are measured in the same well and greater tolerance to differences in amplification efficiencies, which together result in much more robust CN measurements. Furthermore, our data indicates the assays used in this study have a specificity of 100% (95% Confidence Interval = 95.5-100%), allowing us to delineate deletion sizes and locations with great certainty, making it a preferred tool for diagnostics.

Table 4 Copy number values for TaqMan-based ddPCR assays

Assay	TD		22q11DS*	
	Average	Std Err	Average	Std Err
D22S181	2.04	0.03	2.02	0.05
PRODH	2.09	0.08	1.03	0.12
TUPLE1	2.03	0.04	1.02	0.12
COMT	2.06	0.07	1.02	0.12
ZNF74	1.96	0.04	0.97	0.16
PIK4CA	2.03	0.03	1.03	0.12
D22S936	2.05	0.07	1.02	0.12
VPREB1	2.04	0.08	2.08	0.44
Average	2.04	0.09	1.02	0.13

*22q11DS values are only shown for individuals with the 3 Mb deletion spanning the region from *PRODH*-*D22S936*.


Table 5 Copy number values for EvaGreen-based ddPCR assays


Assay	Average	Std Err
DGCR8	1.02	0.32
TRMT2A	1.07	0.47
RANBP1	1.06	0.39
ZDHHC8	1.00	0.37
LOC284865	1.02	0.34
RTN4R	1.02	0.37
DGCR6L	1.04	0.36
SCARF2	1.24	0.53
SHGC-2421	1.37	0.44
HIC2	1.83	0.12
Average	1.09	0.40

Genotype-phenotype correlations

The ddPCR data on the deletion endpoints was used to investigate whether the deletion type/size correlated with various clinical phenotypes including IQ, ADHD, seizures, CHD, hypocalcemia, and thyroid abnormalities (as listed in Table 1) to potentially narrow down a minimal region for disease in the subjects included in this study. The

majority of individuals in our 22q11DS cohort (~62%) had higher (>70) than average IQ scores with a mean score of 73 (± 13), while ADHD was diagnosed in 38% of them. Thyroid abnormalities, seizures and CHD were seen in 14%, 21% and 38% of the participants, respectively. Examination of the clinical phenotypes present in all individuals indicated that many of the clinical features were present in those with the 1.5 Mb deletion defined between locus *PRODH* and *ZNF74* (LCR-A and LCR-B). Interestingly, one of the individuals with an atypical deletion mapping approximately between locus *ZNF74* and *D22S936* (LCR-B and LCR-D), had ID while another individual with an atypical deletion mapping approximately between locus *TUPLE1* and *SHGC-2421* presented with ADHD, seizures, CHD and hypocalcemia and another individual with an atypical deletion mapping between locus *PRODH* and *DGCR6L* presented with seizures and CHD. In addition, the three individuals with the nested deletion (1.5 Mb) had ID and ADHD and one had a more severe phenotype including CHD and seizures. This indicates that other factors (in addition to the 22q11 deletion) are playing a role in the broad variation of the observed phenotype. However, this region of chromosome 22 contains many genes including *HIRA*, *TBX1*, and *DGCR8*, all of which are





thought to be candidate genes for CHD. Although *TBX1* is thought to be the key player for CHD, the presence of individuals with 22q11DS with CHD but without a *TBX1* deletion and the lack of pathogenic mutations identified in the gene suggest that deletion of *TBX1* alone, is not sufficient to give rise to CHD [17,49-51]. Our findings confirm previous reports [32,39] indicating that the correlation between the size or/and position of the deleted region and the broad spectrum of phenotypes is not straightforward and that other factors play a role in contributing to the phenotypes observed in 22q11DS.

One of the genes mapping to the deleted region of chromosome 22q11.2 is *DGCR8*, a gene expected to affect multiple genes as it plays an important role in microRNA (miRNA) biogenesis. miRNAs are small non-coding RNA molecules that are initially transcribed by RNA Polymerase II as primary miRNAs transcripts; then processed into

precursor miRNAs by DROSHA and *DGCR8* (which anchors DROSHA to the primary miRNA) [52-56]. Precursor miRNAs are then exported into the cytoplasm where they are processed into mature miRNAs by the DICER enzyme [57-59]. miRNAs are post-transcriptional gene expression regulators, and can inhibit mRNA translation or promote mRNA degradation [57]. Therefore, hemizygous deletion of *DGCR8* could alter the expression of multiple genes. Several studies in mice and humans have demonstrated a possible correlation of miRNA dysregulation with CHD phenotype in 22q11DS [60-62].

Finally, building genotype-phenotype correlations in 22q11DS can allow for better interventions in individuals with 22q11DS. Similarly, they also function to provide an understanding of the role of the genes in these deleted regions in disorders like ADHD and schizophrenia.




Figure 4 qPCR (SYBR Green) vs. ddPCR (TaqMan) results. Graphic representation of qPCR results for five representative cases for **A)** individuals with 22q11DS and **B)** TD individuals across all 8 assays used in ddPCR (TaqMan). The first individual for each graph represents one where qPCR and ddPCR results were concordant. The y-axis indicates the copy number and the x-axis indicates the position of the 8 assays used in the analysis.

Table 6 Specificity of diagnosis calls by TaqMan-based ddPCR

Outcome ddPCR assay	Positive	Negative	Total
Positive	80	0	80
Negative	0	15	15
Total	80	15	95

Results obtained by TaqMan-based ddPCR are compared to the diagnosis of 22q11DS obtained by FISH using the TUPLE1 gene. Specificity was 100% as all 80 individuals were correctly identified as having 1 copy of the TUPLE1 gene.

Table 7 Specificity of diagnosis calls by qPCR

Outcome qPCR assay	Positive	Negative	Total
Positive	17	0	17
Negative	12	11	23
Total	29	11	40

Results obtained by qPCR are compared to the diagnosis of 22q11DS obtained by FISH using the TUPLE1 gene. Specificity of diagnosis calls for qPCR was 58.6% as ddPCR results, conducted in a subgroup of 40 individuals (29 with 22q11DS and 11 TD) correctly identified 1 copy of the TUPLE1 gene only in 17 individuals with 22q11DS.

Conclusions

In this study we demonstrate the feasibility of ddPCR for detecting and mapping deletions of chromosome 22q11.2. While other methods have been used to elucidate deletion endpoints in individuals with 22q11DS, none have all the qualities required for an effective and reliable diagnostic tool. Additionally, clinical and molecular diagnostics require methodologies that are robust, cost effective and at high throughput.

Although it is not common medical practice to identify the extent of patients' deletions or the location, it may be important, in some cases, to better characterize the LCRs and individual's deletion, size and location. However, many of the genes involved in clinical phenotypes in 22q11DS appear to be located in the common 1.5 Mb deletion region between LCR A-B.

Our findings support the hypothesis that the majority of individuals with 22q11DS have deletion breakpoints located near or within LCRs A and D. Two individuals appear to have breakpoints localized within smaller LCRs scattered along chromosome 22.

Importantly, in this study we show that ddPCR is an ideal technology for detecting 22q11DS and can allow fine mapping of the deleted region using either TaqMan or EvaGreen assays and may be qualified for use in a clinical setting. ddPCR is a high throughput, cost effective technology that allows absolute measure of nucleic acid concentration, providing highly accurate estimations of DNA copy number. Approximately 200 samples can be easily run and analyzed daily, without the difficulties, ambiguity, time and cost of other methodologies, making ddPCR the preferred tool for determining DNA copy number variation in large population screening studies.

Abbreviations

22q11DS: 22q11.2 Deletion Syndrome; ddPCR: droplet digital PCR; CN: Copy Number; CHD: Congenital Heart Disease; ID: Intellectual Disabilities; ADHD: Attention Deficit Hyperactivity Disorder; LCR: Low Copy Repeats; FISH: Fluorescent *In-Situ* Hybridization; MLPA: Multiplex Ligation-Dependent Probe Amplification; qPCR: quantitative PCR; aCHG: array comparative genomic hybridization; TD: Typically Developing Controls; miRNA: microRNA.

Competing interests

Dr. Tassone has received funds from Roche. Dr. Angkustsiri is involved in clinical trials through Roche, Novartis, Seaside, Forest, and SynapDx.

Authors' contributions

VH performed the experiments and participated to the analysis and writing of the manuscript. DM performed the experiments, performed analysis and participated to the writing of the manuscript. JR performed analysis and participated to the writing of the manuscript. KA performed clinical evaluations of the participants in the study and participated in the writing of the manuscript. TS recruited individuals in the study and participated to the writing of the manuscript. FT conceived the study, its design, coordination and analysis and participated to the writing of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The study was supported by the NIH R01HD042974 grant and by Gift funds. We want to thank Nimrah Choudhary for technical help. This work is dedicated to the memory of Matteo.

Author details

¹Department of Biochemistry and Molecular Medicine, UC Davis, 2700 Stockton Blvd, Suite 2102, Sacramento, CA 95817, USA. ²Digital Biology Center, Bio-Rad Laboratories, 5731 West Las Positas Blvd, Pleasanton, CA 94588 USA. ³MIND Institute, UC Davis Medical Center, Wet Lab Room 2418, 2805 50th Street, Sacramento, CA 95817, USA. ⁴Department of Pediatrics, UC Davis Medical Center, Sacramento, CA, USA. ⁵Department of Psychiatry, UC Davis Medical Center, Sacramento, CA, USA.

Received: 7 June 2014 Accepted: 9 September 2014

Published online: 14 October 2014

References

1. Botto LD, May K, Fernhoff PM, Correa A, Coleman K, Rasmussen SA, Merritt RK, O'Leary LA, Wong LY, Elison EM, Mahle WT, Campbell RM: **A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population.** *Pediatrics* 2003, **112**(1 Pt 1):101–107.
2. Goodship J, Cross I, LiLing J, Wren C: **A population study of chromosome 22q11 deletions in infancy.** *Arch Dis Child* 1998, **79**(4):348–351.
3. Tezenas Du Montcel S, Mendizabai H, Ayme S, Levy A, Philip N: **Prevalence of 22q11 microdeletion.** *J Med Genet* 1996, **33**(8):719.
4. Wilson DJ, Burn J, Scambler P, Goodship J: **DiGeorge syndrome: part of CATCH 22.** *J Med Genet* 1993, **30**(10):852–856.
5. McDonald-McGinn DM, Sullivan KE: **Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome).** *Medicine* 2011, **90**(1):1–18.
6. Edelmann L, Pandita RK, Spiteri E, Funke B, Goldberg R, Palanisamy N, Chaganti RS, Magenis E, Shprintzen RJ, Morrow BE: **A common molecular basis for rearrangement disorders on chromosome 22q11.** *Hum Mol Genet* 1999, **8**(7):1157–1167.
7. Shaikh TH, Kurahashi H, Emanuel BS: **Evolutionarily conserved low copy repeats (LCRs) in 22q11 mediate deletions, duplications, translocations, and genomic instability: an update and literature review.** *Genet Med: Off J Am College Med Genet* 2001, **3**(1):6–13.
8. Oskarsdottir S: **Incidence and prevalence of the 22q11 deletion syndrome: a population-based study in Western Sweden.** *Arch Dis Child* 2004, **89**(2):148–151.
9. Kobrynski LJ, Sullivan KE: **Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes.** *Lancet* 2007, **370**(9596):1443–1452.
10. Carlson C, Sirotkin H, Pandita R, Goldberg R, McKie J, Wadey R, Patanjali SR, Weissman SM, Anyane-Yeboah K, Warburton D, Scambler P, Shprintzen R, Kucherlapati R, Morrow BE: **Molecular definition of 22q11 deletions in 151 velo-cardio-facial syndrome patients.** *Am J Hum Genet* 1997, **61**(3):620–629.
11. Garcia-Minaur S, Fantes J, Murray RS, Porteous ME, Strain L, Burns JE, Stephen J, Warner JP: **A novel atypical 22q11.2 distal deletion in father and son.** *J Med Genet* 2002, **39**(10):E62.
12. Rauch A, Zink S, Zweier C, Thiel CT, Koch A, Rauch R, Lascorz J, Huffmeier U, Weyand M, Singer H, Hofbeck M: **Systematic assessment of atypical deletions reveals genotype-phenotype correlation in 22q11.2.** *J Med Genet* 2005, **42**(11):871–876.
13. Rauch A, Pfeiffer RA, Leipold G, Singer H, Tigges M, Hofbeck M: **A novel 22q11.2 microdeletion in DiGeorge syndrome.** *Am J Hum Genet* 1999, **64**(2):659–666.
14. Amati F, Conti E, Novelli A, Bengala M, Diglio MC, Marino B, Giannotti A, Gabrielli O, Novelli G, Dallapiccola B: **Atypical deletions suggest five 22q11.2 critical regions related to the DiGeorge/velo-cardio-facial syndrome.** *Eur J Hum Genet* 1999, **7**(8):903–909.
15. Kurahashi H, Tsuda E, Kohama R, Nakayama T, Masuno M, Imaizumi K, Kamiya T, Sano T, Okada S, Nishisho I: **Another critical region for deletion of 22q11: a study of 100 patients.** *Am J Med Genet* 1997, **72**(2):180–185.
16. Wieser R, Fritz B, Ullmann R, Muller I, Galhuber M, Storlazzi CT, Ramaswamy A, Christiansen H, Shimizu N, Rehder H: **Novel rearrangement of chromosome band 22q11.2 causing 22q11 microdeletion syndrome-like**

- phenotype and rhabdoid tumor of the kidney. *Hum Mutat* 2005, **26**(2):78–83.
17. O'Donnell H, McKeown C, Gould C, Morrow B, Scambler P: **Detection of an atypical 22q11 deletion that has no overlap with the DiGeorge syndrome critical region.** *Am J Hum Genet* 1997, **60**(6):1544–1548.
 18. Saitta SC, McGrath JM, Mensch H, Shaikh TH, Zackai EH, Emanuel BS: **A 22q11.2 deletion that excludes UFD1L and CDC45L in a patient with conotruncal and craniofacial defects.** *Am J Hum Genet* 1999, **65**(2):562–566.
 19. Lu JH, Chung MY, Betau H, Chien HP, Lu JK: **Molecular characterization of tetralogy of fallot within Digeorge critical region of the chromosome 22.** *Pediatr Cardiol* 2001, **22**(4):279–284.
 20. Yamagishi H, Garg V, Matsuoka R, Thomas T, Srivastava D: **A molecular pathway revealing a genetic basis for human cardiac and craniofacial defects.** *Science* 1999, **283**(5405):1158–1161.
 21. Kurahashi H, Nakayama T, Osugi Y, Tsuda E, Masuno M, Imaizumi K, Kamiya T, Sano T, Okada S, Nishisho I: **Deletion mapping of 22q11 in CATCH22 syndrome: identification of a second critical region.** *Am J Hum Genet* 1996, **58**(6):1377–1381.
 22. Verhoeven W, Egger J, Brunner H, de Leeuw N: **A patient with a de novo distal 22q11.2 microdeletion and anxiety disorder.** *Am J Med Genet* 2011, **155A**(2):392–397.
 23. Ben-Shachar S, Ou Z, Shaw CA, Belmont JW, Patel MS, Hummel M, Amato S, Tartaglia N, Berg J, Sutton VR, Lalani SR, Chinault AC, Cheung SW, Lupski JR, Patel A: **22q11.2 distal deletion: a recurrent genomic disorder distinct from DiGeorge syndrome and velocardiofacial syndrome.** *Am J Hum Genet* 2008, **82**(1):214–221.
 24. McQuade L, Christodoulou J, Budarf M, Sachdev R, Wilson M, Emanuel B, Colley A: **Patient with a 22q11.2 deletion with no overlap of the minimal DiGeorge syndrome critical region (MDGCR).** *Am J Med Genet* 1999, **86**(1):27–33.
 25. Rodningen OK, Prescott T, Eriksson AS, Rosby O: **1.4Mb recurrent 22q11.2 distal deletion syndrome, two new cases expand the phenotype.** *Eur J Med Genet* 2008, **51**(6):646–650.
 26. Newbern J, Zhong J, Wickramasinghe RS, Li X, Wu Y, Samuels I, Cherosky N, Karlo JC, O'Loughlin B, Wikenheiser J, Garghesha M, Doughman YQ, Charron J, Ginty DD, Watanabe M, Saitta SC, Snider WD, Landreth GE: **Mouse and human phenotypes indicate a critical conserved role for ERK2 signaling in neural crest development.** *Proc Natl Acad Sci USA* 2008, **105**(44):17115–17120.
 27. Verhagen JM, Diderich KE, Oudesluijs G, Mancini GM, Eggink AJ, Verkleij-Hagoort AC, Groenenberg JA, Willems PJ, du Plessis FA, de Man SA, Srebnik ML, van Opstal D, Hulsman LO, van Zutven LJ, Wessels MW: **Phenotypic variability of atypical 22q11.2 deletions not including TBX1.** *Am J Med Genet* 2012, **158A**(10):2412–2420.
 28. Breckpot J, Thienpont B, Bauters M, Tranchevent LC, Gewillig M, Allegaert K, Vermeesch JR, Moreau Y, Devriendt K: **Congenital heart defects in a novel recurrent 22q11.2 deletion harboring the genes CRKL and MAPK1.** *Am J Med Genet* 2012, **158A**(3):574–580.
 29. Ogilvie CM, Ahn JW, Mann K, Roberts RG, Flinter F: **A novel deletion in proximal 22q associated with cardiac septal defects and microcephaly: a case report.** *Mol Cytogenet* 2009, **2**:9.
 30. D'Angelo CS, Jehee FS, Koiffmann CP: **An inherited atypical 1 Mb 22q11.2 deletion within the DGS/VCFS 3 Mb region in a child with obesity and aggressive behavior.** *Am J Med Genet* 2007, **143A**(16):1928–1932.
 31. Mikhail FM, Descartes M, Piotrowski A, Andersson R, de Diaz Stahl T, Komorowski J, Bruder CE, Dumanski JP, Carroll AJ: **A previously unrecognized microdeletion syndrome on chromosome 22 band q11.2 encompassing the BCR gene.** *Am J Med Genet* 2007, **143A**(18):2178–2184.
 32. Fernandez L, Nevado J, Santos F, Heine-Suner D, Martinez-Glez V, Garcia-Minaur S, Palomo R, Delicado A, Pajares IL, Palomares M, Garcia-Guereta L, Valverde E, Hawkins F, Lapunzina P: **A deletion and a duplication in distal 22q11.2 deletion syndrome region. Clinical implications and review.** *BMC Med Genet* 2009, **10**:48.
 33. Garavelli L, Rosato S, Wischmeijer A, Gelmini C, Esposito A, Mazzanti L, Franchi F, De Crescenzo A, Palumbo O, Carella M, Riccio A: **22q11.2 Distal Deletion Syndrome: Description of a New Case with Truncus Arteriosus Type 2 and Review.** *Mol Syndromol* 2011, **2**(1):35–44.
 34. Vorstman JA, Jalali GR, Rappaport EF, Hacker AM, Scott C, Emanuel BS: **MLPA: a rapid, reliable, and sensitive method for detection and analysis of abnormalities of 22q.** *Human Mutat* 2006, **27**(8):814–821.
 35. Weksberg R, Hughes S, Moldovan L, Bassett AS, Chow EW, Squire JA: **A method for accurate detection of genomic microdeletions using real-time quantitative PCR.** *BMC Genomics* 2005, **6**:180.
 36. Mantripragada KK, Tapia-Paez I, Blennow E, Nilsson P, Wedell A, Dumanski JP: **DNA copy-number analysis of the 22q11 deletion-syndrome region using array-CGH with genomic and PCR-based targets.** *Int J Mol Med* 2004, **13**(2):273–279.
 37. Miller KA: **FISH Diagnosis of 22q11.2 Deletion Syndrome.** *Newborn Infant Nurs Rev* 2008, **8**(1):e11–e19.
 38. Jalali GR, Vorstman JA, Errami A, Vijzelaar R, Biegel J, Shaikh T, Emanuel BS: **Detailed analysis of 22q11.2 with a high density MLPA probe set.** *Hum Mutat* 2008, **29**(3):433–440.
 39. Bittel DC, Yu S, Newkirk H, Kibiryeva N, Holt A 3rd, Butler MG, Cooley LD: **Refining the 22q11.2 deletion breakpoints in DiGeorge syndrome by aCGH.** *Cytogen Genome Res* 2009, **124**(2):113–120.
 40. Coffa J, van de Wiel MA, Diosdado B, Carvalho B, Schouten J, Meijer GA: **MLPAAnalyzer: data analysis tool for reliable automated normalization of MLPA fragment data.** *Cell Oncol* 2008, **30**(4):323–335.
 41. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G: **Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification.** *Nucleic Acids Res* 2002, **30**(12):e57.
 42. Frigerio M, Passeri E, de Filippis T, Rusconi D, Valaperta R, Carminati M, Donnangelo A, Costa E, Persani L, Finelli P, Corbetta S: **SNPs and real-time quantitative PCR method for constitutional allelic copy number determination, the VPRED1 marker case.** *BMC Med Genet* 2011, **12**:61.
 43. Schwab CJ, Jones LR, Morrison H, Ryan SL, Yigittop H, Schouten JP, Harrison CJ: **Evaluation of multiplex ligation-dependent probe amplification as a method for the detection of copy number abnormalities in B-cell precursor acute lymphoblastic leukemia.** *Genes Chromosomes Cancer* 2010, **49**(12):1104–1113.
 44. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz AJ, Bright IJ, Lucero MY, Hiddessen AL, Legler TC, Kitano TK, Hodel MR, Petersen JF, Wyatt PW, Steenblock ER, Shah PH, Bousse LJ, Troup CB, Mellen JC, Wittmann DK, Erndt NG, Cauley TH, Koehler RT, So AP, Dube S, Rose KA, Montesclaros L, Wang S, Stumbo DP, Hodges SP, et al.: **High-throughput droplet digital PCR system for absolute quantitation of DNA copy number.** *Anal Chem* 2011, **83**(22):8604–8610.
 45. Pinheiro LB, Coleman VA, Hindson CM, Herrmann J, Hindson BJ, Bhat S, Emslie KR: **Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification.** *Anal Chem* 2012, **84**(2):1003–1011.
 46. Wechsler D: *Wechsler intelligence scale for children—Fourth Edition (WISC-IV).* San Antonio, TX: The Psychological Corporation; 2003.
 47. Swanson J: *SNAP-IV Scale.* Irvine, Calif: University of California Child Development Center; 1994.
 48. Wechsler D: *Wechsler abbreviated scale of intelligence.* San Antonio, TX: Psychological Corporation; 1999.
 49. Lindsay EA, Botta A, Jurecic V, Carattini-Rivera S, Cheah YC, Rosenblatt HM, Bradley A, Baldini A: **Congenital heart disease in mice deficient for the DiGeorge syndrome region.** *Nature* 1999, **401**(6751):379–383.
 50. Gong W, Gottlieb S, Collins J, Blescia A, Dietz H, Goldmuntz E, McDonald-McGinn DM, Zackai EH, Emanuel BS, Driscoll DA, Budarf ML: **Mutation analysis of TBX1 in non-deleted patients with features of DGS/VCFS or isolated cardiovascular defects.** *J Med Genet* 2001, **38**(12):E45.
 51. Conti E, Grifone N, Sarkozy A, Tandoi C, Marino B, Digilio MC, Mingarelli R, Pizzuti A, Dallapiccola B: **DiGeorge subtypes of nonsyndromic conotruncal defects: evidence against a major role of TBX1 gene.** *Eur J Hum Genet* 2003, **11**(4):349–351.
 52. Ambros V: **microRNAs: tiny regulators with great potential.** *Cell* 2001, **107**(7):823–826.
 53. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ: **Processing of primary microRNAs by the Microprocessor complex.** *Nature* 2004, **432**(7014):231–235.
 54. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, Shiekhattar R: **The Microprocessor complex mediates the genesis of microRNAs.** *Nature* 2004, **432**(7014):235–240.
 55. Han J, Lee Y, Yeom KH, Nam JW, Heo I, Rhee JK, Sohn SY, Cho Y, Zhang BT, Kim VN: **Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex.** *Cell* 2006, **125**(5):887–901.
 56. Lai EC: **microRNAs: runts of the genome assert themselves.** *Current Biol* 2003, **13**(23):R925–R936.

57. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Radmark O, Kim S, Kim VN: **The nuclear RNase III Drosha initiates microRNA processing.** *Nature* 2003, **425**(6956):415–419.
58. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN: **The Drosha-DGCR8 complex in primary microRNA processing.** *Genes Dev* 2004, **18**(24):3016–3027.
59. Wang Y, Medvid R, Melton C, Jaenisch R, Belloch R: **DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal.** *Nat Genet* 2007, **39**(3):380–385.
60. Rao PK, Toyama Y, Chiang HR, Gupta S, Bauer M, Medvid R, Reinhardt F, Liao R, Krieger M, Jaenisch R, Lodish HF, Belloch R: **Loss of cardiac microRNA-mediated regulation leads to dilated cardiomyopathy and heart failure.** *Circ Res* 2009, **105**(6):585–594.
61. Huang ZP, Chen JF, Regan JN, Maguire CT, Tang RH, Dong XR, Majesky MW, Wang DZ: **Loss of microRNAs in neural crest leads to cardiovascular syndromes resembling human congenital heart defects.** *Arterioscler Thromb Vasc Biol* 2010, **30**(12):2575–2586.
62. de la Morena MT, Eitson JL, Dozmorov IM, Belkaya S, Hoover AR, Anguiano E, Pascual MV, van Oers NS: **Signature MicroRNA expression patterns identified in humans with 22q11.2 deletion/DiGeorge syndrome.** *Clin Immunol* 2013, **147**(1):11–22.

doi:10.1186/s12881-014-0106-5

Cite this article as: Hwang *et al.*: Mapping the deletion endpoints in individuals with 22q11.2 Deletion Syndrome by droplet digital PCR. *BMC Medical Genetics* 2014 **15**:106.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

